February XX, 2012

Dear Pharmacist,

The intent of this letter is to provide you with notice of a short-term disruption in our supply of Voltaren® Gel (diclofenac sodium topical gel) 1%.

As a brief background, production of Voltaren Gel has been temporarily suspended by our manufacturer to allow implementation of manufacturing process improvements. As a result of these improvements, we anticipate that there may be a short-term disruption in the supply of these products to patients. This temporary supply disruption is not related to the efficacy or safety of Voltaren Gel. We anticipate the market will be re-supplied by early second quarter 2012.

The following sizes may be impacted:

<table>
<thead>
<tr>
<th>NDC</th>
<th>Description</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>63481-0684-47</td>
<td>Voltaren Gel</td>
<td>1 tube of 100 g</td>
</tr>
<tr>
<td>63481-0684-03</td>
<td>Voltaren Gel 3-Pack</td>
<td>3 tubes of 100 g</td>
</tr>
<tr>
<td>63481-0684-05</td>
<td>Voltaren Gel 5-Pack</td>
<td>5 tubes of 100 g</td>
</tr>
</tbody>
</table>

Endo’s principal concern is the health, well-being, and the continuity of care for patients using Voltaren Gel. We are working closely with our manufacturing facility to minimize patient disruptions.

We will provide you with an update on the supply status and any new developments as soon as possible.

**Indication**
Voltaren® Gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. Voltaren Gel has not been evaluated for use on the spine, hip, or shoulder.

**Important Safety Information for Voltaren Gel**

**Cardiovascular Risk**
- Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk [see Warnings and Precautions].
- Voltaren Gel is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications].

**Gastrointestinal Risk**
- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events [see Warnings and Precautions].

(continued on next page)
Important Safety Information for Voltaren® Gel (cont’d)

The most common adverse reactions reported in Voltaren Gel clinical trials were application site reactions in 7% of treated patients. With all NSAIDs there may be an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal.

NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.

The use of Voltaren Gel is contraindicated in patients with a known hypersensitivity to diclofenac.

Voltaren Gel should not be administered in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

Voltaren Gel should not be used in combination with other oral NSAIDs or aspirin because of the potential for increased adverse effects. Similarly, combined use of Voltaren Gel with other topical products, such sunscreens and cosmetics, on the same skin area has not been tested and should be avoided because of the potential to alter local tolerability and absorption.

NSAIDs, including Voltaren Gel, can lead to high blood pressure or worsening of high blood pressure, which may add to the increased risk of heart attack and stroke.

There is a potential for elevation in liver function tests during treatment with diclofenac containing products.

Safety and effectiveness in pediatric patients have not been established.

Please see accompanying full Prescribing Information.

For additional information on Voltaren Gel, please visit www.VoltarenGel.com.

Please contact your Endo sales representative should you have any additional questions or Endo customer service at 1-800-462-3636.

Sincerely,

Frank Casty, MD, FACP
Senior Vice President Clinical Development and Chief Medical Officer